Ionis Pharmaceuticals Inc. (IONS) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) Comparing side by side

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals Inc. 568.84M 14.29 65.45M 0.51 104.36
Spectrum Pharmaceuticals Inc. 108.50M 10.79 99.35M -0.60 0.00

In table 1 we can see Ionis Pharmaceuticals Inc. and Spectrum Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides us Ionis Pharmaceuticals Inc. and Spectrum Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals Inc. -11.51% -8.8% -2.4%
Spectrum Pharmaceuticals Inc. -91.57% -30.6% -22.1%

Risk & Volatility

A beta of 2.38 shows that Ionis Pharmaceuticals Inc. is 138.00% more volatile than S&P 500. Competitively, Spectrum Pharmaceuticals Inc.’s beta is 2.28 which is 128.00% more volatile than S&P 500.


The Current Ratio of Ionis Pharmaceuticals Inc. is 8 while its Quick Ratio stands at 8. The Current Ratio of rival Spectrum Pharmaceuticals Inc. is 2.6 and its Quick Ratio is has 2.6. Ionis Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Spectrum Pharmaceuticals Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Ionis Pharmaceuticals Inc. and Spectrum Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ionis Pharmaceuticals Inc. 0 0 0 0.00
Spectrum Pharmaceuticals Inc. 0 0 2 3.00

Spectrum Pharmaceuticals Inc. on the other hand boasts of a $24 consensus price target and a 117.19% potential upside.

Institutional & Insider Ownership

Roughly 89.5% of Ionis Pharmaceuticals Inc. shares are held by institutional investors while 84% of Spectrum Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 0.2% of Ionis Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 0.6% of Spectrum Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ionis Pharmaceuticals Inc. -8.51% -1.82% 19.71% 16.26% 1.5% 6.02%
Spectrum Pharmaceuticals Inc. -12.03% -3.93% -38.1% -36.05% -33.05% -32.88%

For the past year Ionis Pharmaceuticals Inc. had bullish trend while Spectrum Pharmaceuticals Inc. had bearish trend.


Ionis Pharmaceuticals Inc. beats on 11 of the 12 factors Spectrum Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.